Spire Healthcare shareholders will vote on 30 October on a board-backed 250p-per-share cash offer from a consortium led by Toscafund, as dealing disclosures continue to flow.
Spire Healthcare (LSE:SPI), the FTSE 250 private hospital group, is moving through the final stages of a Takeover process that began in May. The company remains in an offer period, and over recent days a large number of Takeover Code dealing disclosures have been filed by institutional investors, reflecting active trading in the shares ahead of the Shareholder vote. The scheme document setting out the details of the proposed Acquisition was published on 29 September.
The terms of the offer
On 7 September Spire agreed a takeover by Tulip UK Bidco, a newly formed company owned by funds managed or advised by Toscafund Asset Management, THCP Advisory and Ares Management. The offer is 250p in cash per share, which values Spire's Equity at about £1.03bn and implies an enterprise value, including debt, of about £2.31bn. The price represents a premium of roughly 66% to the undisturbed share price of 150.4p on 13 May, the day before Toscafund's non-binding proposal at the same level became public.
The deal also includes a partial share alternative, under which eligible shareholders can elect to receive unlisted securities in the acquiring group instead of cash, subject to a cap. Spire's directors unanimously back the cash offer, which they regard as fair and reasonable, but have taken no position on the alternative. Directors who hold shares have irrevocably undertaken to vote in favour.
Timetable and conditions
The acquisition is being implemented through a court-sanctioned scheme of arrangement. The court meeting is scheduled for 30 October 2026 at noon, followed by a general meeting at 12.15pm. Proxy forms must be submitted by 28 October. Spire expects the scheme to become effective in the fourth quarter of 2026 or the first quarter of 2027, with a long-stop date of 4 March 2027, which can be extended in certain circumstances.
The scheme requires approval from shareholders at both meetings, sanction by the court, and the satisfaction or Waiver of other conditions set out in the scheme document. There remains no certainty that the transaction will complete.
Leadership changes and the road to this point
The agreed deal came after a lengthy process. Spire ended earlier talks with Private Equity groups Triton and Bridgepoint in March, before Toscafund, already its second-largest shareholder, made its approach. The put-up-or-shut-up deadline was extended several times over the summer while Due Diligence and financing arrangements were completed.
Alongside the agreed offer, Spire announced management changes. Chief executive Justin Ash is retiring, with David Sloman serving as interim chief executive while a permanent successor is sought, and chair Ian Cheshire has stepped down, with Debbie White acting as interim chair.
For FTSE 250 investors, the shares are now likely to trade largely in relation to the 250p offer price, with any gap reflecting the time to completion and the perceived risk that the deal does not proceed. The bid also adds to a wider pattern of private Capital targeting UK-listed mid-caps, where buyers argue that public market valuations do not fully reflect underlying asset values. In Spire's case, its portfolio of hospitals and clinics, together with growing Demand for private treatment as NHS waiting lists remain elevated, has been central to the Investment case put forward by the bidders.
Shareholders will be asked to vote on the scheme at the court meeting by the required majorities, and the outcome will determine whether the deal can proceed to the court sanction stage.
_11_18_2026_06_43_20_247880.jpg)





Please wait processing your request...